company-logo

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

Caribou Biosciences Dividend Announcement

Caribou Biosciences does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
Stay tuned for updates on Caribou Biosciences dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Caribou Biosciences Dividend History

Caribou Biosciences Dividend Yield

Caribou Biosciences current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Caribou Biosciences stock? Use our calculator to estimate your expected dividend yield:

Caribou Biosciences Financial Ratios

P/E ratio-1.43
PEG ratio0.14
P/B ratio0.57
ROE-34.76%
Payout ratio0.00%
Current ratio8.75
Quick ratio8.75
Cash Ratio1.22

Caribou Biosciences Dividend FAQ

Does Caribou Biosciences stock pay dividends?
Caribou Biosciences does not currently pay dividends to its shareholders.
Has Caribou Biosciences ever paid a dividend?
No, Caribou Biosciences has no a history of paying dividends to its shareholders. Caribou Biosciences is not known for its dividend payments.
Why doesn't Caribou Biosciences pay dividends?
There are several potential reasons why Caribou Biosciences would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Caribou Biosciences ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Caribou Biosciences has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Caribou Biosciences a dividend aristocrat?
Caribou Biosciences is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Caribou Biosciences a dividend king?
Caribou Biosciences is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Caribou Biosciences a dividend stock?
No, Caribou Biosciences is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Caribou Biosciences stocks?
To buy Caribou Biosciences you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Caribou Biosciences stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.